Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Supaglutide

Stage Phase 2/3Stale

Sponsor Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.

Route oral and injection

Class GLP-1 RA

Mechanism long-acting GLP-1 receptor agonist

Sources

registry, as of 2021-09-17Stale

https://clinicaltrials.gov/study/NCT03745885

A Study of the Efficacy and Safety of Supaglutide in Healthy Participants. Overall status COMPLETED. Phases PHASE1. Lead sponsor Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.. Enrollment 48. Conditions Diabetes Mellitus, Type 2. This study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the investigational drug Supaglutide proposed dosing once (or twice) weekly in Chinese healthy subjects.

ClinicalTrials.gov NCT03745885 protocol and results modules

registry, as of 2024-12-06Stale

https://clinicaltrials.gov/study/NCT04998032

A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients On Metformin Treatment(SUPER-2). Overall status COMPLETED. Phases PHASE2,PHASE3. Lead sponsor Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.. Enrollment 620. Conditions Type2 Diabetes. This is a study to evaluate the efficacy and safety of Supaglutide injection in the treatment of type 2 diabetes patients with poor glycemic control after metformin treatment. This trial includes dosage determination (Phase IIb) and efficacy confirmation stage(Phase III ). The p

ClinicalTrials.gov NCT04998032 protocol and results modules

registry, as of 2024-08-07Stale

https://clinicaltrials.gov/study/NCT04994288

A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients(SUPER-1). Overall status COMPLETED. Phases PHASE2,PHASE3. Lead sponsor Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.. Enrollment 547. Conditions Type2 Diabetes. This is a study to evaluate the efficacy and safety of Supaglutide injection in the treatment of type 2 diabetes patients with poor glycemic control after diet and exercise intervention. This trial includes dosage determination (Phase IIb) and efficacy confirmation stage(Phase I

ClinicalTrials.gov NCT04994288 protocol and results modules

registry, as of 2021-09-17Stale

https://clinicaltrials.gov/study/NCT04314622

A Study of Supaglutide in Chinese Type 2 Diabetes Patients. Overall status COMPLETED. Phases PHASE2. Lead sponsor Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.. Enrollment 40. Conditions Diabetes Mellitus, Type 2. A study on the safety, efficacy, pharmacokinetics and pharmacodynamics of Supaglutide dosing weekly and bi-weekly in patients with type 2 diabetes mellitus.

ClinicalTrials.gov NCT04314622 protocol and results modules

registry, as of 2024-09-20Stale

https://clinicaltrials.gov/study/NCT06605287

The Progress of Diabetes After Supaglutide Treatment in Type 2 Diabetes Patients. Overall status UNKNOWN. Phases not stated. Lead sponsor Nanjing First Hospital, Nanjing Medical University. Enrollment 100. Conditions Type 2 Diabetes Mellitus. Glucagon like peptide-1 receptor agonist (GLP-1RA) can enhance insulin secretion and inhibit glucagon secretion in a glucose concentration dependent manner, delay gastric emptying, and reduce food intake through central appetite inhibition, thus achieving the effect of lowering g

ClinicalTrials.gov NCT06605287 protocol and results modules

publication, as of 2026-10-13Stale

https://pubmed.ncbi.nlm.nih.gov/42870102/

Efsubaglutide Alfa: A Comprehensive Pharmacological Review. Efsubaglutide alfa (also known as supaglutide) is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) engineered as a GLP-1 analogue fused to a human immunoglobulin G2 (IgG2) fragment crystallisable (Fc) domain. This narrative review summarises published and publicly ava

PMID 42870102

Studies

A Study of the Efficacy and Safety of Supaglutide in Healthy Participants

Registry NCT03745885

Phase Phase 1

Status Completed

Enrollment 48

Start 2018-12-04

Primary completion 2019-06-10

Study completion 2019-12-13

0.15mg Supaglutide or placebo

Dose 0.15mg

Regimen weekly

Population Diabetes Mellitus, Type 2

0.375mg Supaglutide or placebo

Dose 0.375mg

Regimen weekly

Population Diabetes Mellitus, Type 2

0.75mg Supaglutide or placebo

Dose 0.75mg

Regimen weekly

Population Diabetes Mellitus, Type 2

1.5mg Supaglutide or placebo

Dose 1.5mg

Regimen weekly

Population Diabetes Mellitus, Type 2

3.0mg Supaglutide or placebo

Dose 3.0mg

Regimen weekly

Population Diabetes Mellitus, Type 2

A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients On Metformin Treatment(SUPER-2)

Registry NCT04998032

Phase Phase 2/3

Status Completed

Enrollment 620

Start 2021-10-12

Primary completion 2023-06-15

Study completion 2023-08-13

supaglutide RP3D dose+metformin

Regimen once weekly

Weeks 52

Comparator placebo

Population Type2 Diabetes

placebo+metformin

Regimen once weekly

Weeks 52

Population Type2 Diabetes

A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients(SUPER-1)

Registry NCT04994288

Phase Phase 2/3

Status Completed

Enrollment 547

Start 2021-08-03

Primary completion 2023-06-20

Study completion 2023-08-16

Supaglutide RP3D high dose

Regimen once weekly

Comparator placebo

Population Type2 Diabetes

supaglutide RD3D Low dose

Regimen once weekly

Comparator placebo

Population Type2 Diabetes

placebo

Regimen once weekly

Population Type2 Diabetes

A Study of Supaglutide in Chinese Type 2 Diabetes Patients

Registry NCT04314622

Phase Phase 2

Status Completed

Enrollment 40

Start 2020-04-14

Primary completion 2020-10-25

Study completion 2021-03-16

Supaglutide (Part A)

Regimen weekly

Comparator placebo

Population Diabetes Mellitus, Type 2

Placebo(Part A)

Regimen weekly

Population Diabetes Mellitus, Type 2

Supaglutide (Part B)

Regimen weekly

Comparator placebo

Population Diabetes Mellitus, Type 2

Placebo (Part B)

Regimen weekly

Population Diabetes Mellitus, Type 2

The Progress of Diabetes After Supaglutide Treatment in Type 2 Diabetes Patients

Registry NCT06605287

Enrollment 100

Start 2023-03-13

Primary completion 2024-12-31

Study completion 2025-12-31

Supaglutide Treatment

Population Type 2 Diabetes Mellitus